自己幹細胞・非幹細胞治療市場レポート：2030年までの動向、予測、競合分析

自己幹細胞・非幹細胞治療の動向と予測

世界の自己幹細胞・非幹細胞治療市場は、2024年から2030年までのCAGRが10.2%で、2030年までに推定130億米ドルに達すると予測されます。この市場の主な促進要因は、低侵襲治療に対する需要の高まり、幹細胞および非幹細胞を用いた治療法の急速な技術進歩、再生医療の利用を促進するための政府支援の高まりです。世界の自己幹細胞・非幹細胞治療市場の将来は、病院や外来手術センター市場での機会により有望視されています。

• Lucintelの予測では、がんと腫瘍は、がんの罹患率と治療法の拡大とともに、自己幹細胞治療の利用が増加しているため、予測期間中に最も高い成長が見込まれています。
• 北米は、慢性疾患の有病率の高さ、低侵襲処置に対する大きな需要の存在、同地域における有利な政府償還政策の利用可能性により、予測期間中に最も高い成長を示すと予想されます。

自己幹細胞・非幹細胞治療市場の新たな動向

自己幹細胞・非幹細胞治療市場の新たな動向として、技術の進化、規制の変化、臨床応用の変化が挙げられます。これらは再生医療の未来を再構築し、市場の成長を確実なものにする動向です。

• 個別化医療の重視：医薬品の個別化の進展は、自己幹細胞治療市場における個別化重視の高まりの一部です。患者の特定の遺伝子プロファイルを通じてもたらされる高度な個別化は、副作用を抑えながら効率を高めるという点で大きな成果を上げています。従って、この動向は、患者の予後をより良くするために、よりカスタマイズされた治療への後押しとなっています。
• 細胞加工技術の進歩：新しい細胞加工技術が幹細胞治療の効果を高めています。自動化された細胞加工技術や、より高品質で多数の治療用細胞を得るための細胞拡大法などが、その技術力です。これにより、自己幹細胞治療の実現可能性と拡張性がさらに高まることは間違いありません。
• 臨床応用の拡大：幹細胞と非幹細胞を用いた治療法の臨床応用は、爆発的な成長を遂げようとしています。心臓血管系、神経系、整形外科的疾患などに影響を与える疾患や損傷に対する新たな治療法の研究が進められています。これにより、再生医療が開発される基盤が強化されるとともに、市場成長の機会も増え続けています。
• 非幹細胞療法の開発：組織工学や遺伝子編集など、純粋な幹細胞を用いない治療法の開発が進んでいます。これらは、幹細胞を用いた従来の治療法を補う、再生医療の新たな手法です。このような発明は治療の選択肢を増やし、市場成長の原動力となります。
• 規制の進展と承認：規制当局の継続的な取り組みによるこの分野のさらなる発展は、新たな治療法の承認と商業化を促進し続けると思われます。革新的な治療法に対する支援の増加とともに、規制プロセスの合理化は、自己幹細胞や非幹細胞を用いた治療法のさらなる開発と適応を促し、より良い市場参入を可能にし、技術革新のペースを加速させると思われます。

このような新興国の動向は、個別化医療の進歩、細胞加工技術の向上、臨床用途の拡大、他の代替療法の開発、スムーズな規制当局の承認などによって、自己幹細胞・非幹細胞治療市場に革命をもたらしつつあります。このことがイノベーションを促進し、再生医療の有効性を継続的に高めています。

自己幹細胞・非幹細胞治療市場における最近の動向

自己幹細胞と非幹細胞を用いた治療における主な発展には、技術と臨床の変化を示すものがあります。このことは、この研究領域がダイナミックであり、健康への影響が増大していることを示しています。

• 新しい治療法の承認FDAのような様々な機関が新たな自己幹細胞治療を承認したことで、治療の幅が広がり、慢性疾患や怪我に苦しむ患者に治療の選択肢が広がりました。その他の活動としては、心血管疾患や自己免疫疾患に対する先進的な治療が挙げられ、この分野の進歩を反映する活発な分野です。
• 細胞加工における革新：細胞加工の新技術には、幹細胞治療をより効果的で強力なものにする自動化システムや拡大手法の改良が含まれます。このような技術の進歩は、質の高い治療細胞の生成と治療へのアクセスの向上を促進します。
• 幹細胞以外の治療法の成長：また、組織工学や遺伝子治療のような非幹細胞ベースの治療においても、市場は大きく成長していると推定されます。これらの分野における新たなフロンティアは、再生医療に向けた様々なアプローチを開発し、幹細胞の応用に基づく従来のアプローチを補完しています。
• 調査と臨床試験の拡大：自己幹細胞治療と非幹細胞治療の両方における調査や臨床試験が増加する一方で、新たな治療法の開発、新たな応用法の研究、治療効果や安全性に関する理解の深化も進んでいます。
• 個別化治療の進歩：この市場における主要な動向のひとつは、患者のプロファイルに合わせた個別化治療の創出です。遺伝子型と臨床情報に基づくカスタム治療は、個別化医療に向かうことで治療成績を向上させ、有害事象を減少させています。

これらの追加は、新しい治療法、細胞加工技術、拡大研究、臨床試験、個別化治療アプローチにおいて、自己幹細胞・非幹細胞治療市場に影響を与えています。このことが、再生医療をさらに有効なレベルに押し上げる成長の原動力となっています。

自己幹細胞・非幹細胞治療市場の戦略的成長機会

自己幹細胞・非幹細胞治療市場における成長機会は、技術の進歩や応用の拡大とともに出現し続け、再生医療分野における未来を形成し、市場をさらに拡大させています。

• 腫瘍治療：さらに、幹細胞治療ががんの治療と回復のために研究されているがん領域は、大きな成長機会となっています。先進的な細胞治療や組織工学技術によって、様々なタイプのがんの管理や治療に新しい治療法が提供され、市場の可能性が高まっています。
• 心臓血管への応用：心臓血管への応用は引き続き主要な成長分野の一つであり、心臓の修復と再生のための幹細胞治療の開発も行われます。心血管系疾患に対する細胞ベースの治療は、アンメットニーズを満たし、治療の選択肢を広げるイノベーションを生み出し、市場の成長を牽引しています。
• 神経疾患：神経疾患の治療は、新たな成長機会と考えられます。パーキンソン病や脊髄損傷は、幹細胞を用いる治療と用いない治療の両方が研究されている疾患の一例です。このように、効果的な治療への新たな道が開かれるとともに、市場応用の可能性が広がっています。
• 整形外科的外傷：その他の成長分野として、整形外科的外傷や病態が挙げられ、軟骨の修復や骨の再生に幹細胞治療が検討されています。最近の再生医療の進歩により、筋骨格系の損傷に新たな解決策が提供され始め、回復が改善され、市場の成長に寄与しています。
• 糖尿病のモニタリング：すなわち、インスリン産生細胞の再生を含む幹細胞治療による糖尿病の管理です。糖尿病細胞を用いた治療イノベーションは、糖尿病の管理と患者の予後改善に新たなフロンティアを開きつつあります。

自己幹細胞・非幹細胞治療における戦略的成長機会は、腫瘍学、心臓血管への応用、神経疾患、整形外科的損傷、糖尿病管理に関連する進歩によってもたらされます。これは、再生医療の範囲を広げ、幅広い治療領域にわたるイノベーションを推進するものです。

自己幹細胞・非幹細胞治療市場の促進要因・課題

自己幹細胞・非幹細胞治療市場の成長と動向の方向性を形作るのは、主な市場促進要因・課題です。流動要因や成長要因としては、技術的進歩、経済的要因、規制上の考慮事項が市場を形成する上で影響力のある役割を果たしています。

自己幹細胞・非幹細胞治療市場を牽引する要因としては、以下のようなものが挙げられます：

1.技術の進歩：画像処理、細胞加工、治療技術における技術進歩は、市場の成長に寄与する要因のひとつです。細胞処理の自動化や高度な遺伝子編集は、幹細胞・非幹細胞治療の有効性と効率を向上させる最近の革新的なコンセプトの一つであり、臨床応用の幅を広げています。

2.再生医療への需要の高まり：再生医療に対する需要の高まりは、市場を牽引する大きな要因の一つです。そのため、患者やヘルスケアプロバイダーは慢性疾患や変性疾患に対する高度な治療法をますます必要とするようになっており、幹細胞治療と非幹細胞治療の両方が広く採用されるようになっています。このことは、市場のさらなる成長と技術革新を促進します。

3.臨床応用の拡大：幹細胞治療と非幹細胞治療の臨床応用の拡大が、この市場を牽引しています。さらに、がん、心血管疾患、神経疾患など、様々な疾患に対する新しい治療法が、再生医療の範囲を拡大し、市場機会を増大させています。

4.研究開発投資の拡大：研究開発への投資の増加は、自己幹細胞・非幹細胞を用いた治療市場へのイノベーションを促進します。このような資金は官民両セクターから拠出され、市場の改善と競争を促進する新たな治療法や技術の創造と開発を支えています。

5.規制当局別支援と承認：新治療法の承認と商業化のための規制当局による明確な道筋、市場アクセスの改善、新治療法の迅速な導入などです。

自己幹細胞・非幹細胞治療市場における課題は以下の通りです：

1.規制上のハードル：複雑な規制要件を克服し、新種の治療法を提供することで承認を可能にすることは複雑です。また、幹細胞や非幹細胞を用いた新しい治療法のイントロダクションや採用に際して、規制の地域差は非常に厳しいです。

2.高い開発コスト：高コストは、先進的な治療法の開発や製造過程における主要な課題の一つです。これは、研究開発、製造に関連するコストに起因するものであり、特に価格に敏感な市場にとっては、利用しやすさや購入しやすさが制限される可能性があります。市場に広く浸透するためには、コスト管理が絶対的に必要となってきます。

3.倫理・安全性の問題：幹細胞を用いた研究や治療法に関する倫理的・安全性の問題は、最も大きな課題の一つと考えられています。インフォームド・コンセント、リスクの可能性、長期的な治療結果などの問題は、社会的な信頼を獲得し、規制当局の承認を得るために、深く議論されなければなりません。

自己幹細胞・非幹細胞治療市場の成長促進要因は、技術の進歩、再生医療に対する需要の増加、臨床応用の拡大、研究開発投資の増加、規制当局の支援です。主なボトルネックは、規制上のハードル、高い開発コスト、倫理的問題などです。これらの市場促進要因・課題への対応にますます力を入れることで、市場のより良い成長とイノベーションが達成されるであろう。

自己幹細胞・非幹細胞ベースのセグメント別治療法

本調査では、世界の自己幹細胞・非幹細胞治療の製品タイプ別、種類別、用途別、最終用途別、地域別の予測を掲載しています。

自己幹細胞・非幹細胞治療市場の国別展望

自己幹細胞・非幹細胞治療市場は、技術革新と臨床応用の広がりにより、最近の動向で大きく発展しています。これらは米国、中国、ドイツ、インド、日本で起こっており、再生医療とその主流医療システムへの組み込みにおける世界の発展を反映しています。

• 米国：米国では、自己幹細胞治療がFDAの認可を受け、新たな治療法として臨床試験が開始されています。この市場では、心血管疾患や自己免疫疾患など、様々な適応症に対する個別化治療が活発化しています。細胞の加工と保存に関する技術の向上が、こうした治療法の有効性と利用しやすさを高めています。
• 中国：このように、中国は幹細胞治療と非幹細胞治療の両分野で進歩しており、臨床研究と商業化の両面で急速な成長を遂げています。最近の動向としては、幹細胞バンキングサービスの拡大や、再生医療に関連する研究への資金提供の増加が挙げられます。中国の研究機関は、先進的な幹細胞技術を用いて、がんや神経疾患の新たな治療法を模索しています。
• ドイツ：しかしながら、ドイツは自己幹細胞治療を日常的な臨床管理に組み込むという点では先進国です。最近の動向としては、整形外科的疾患や皮膚科的疾患に対する新しい幹細胞治療の導入が挙げられます。ドイツにおける治療の実施に関しては、品質管理と患者の安全性が非常に高い水準で強調されています。
• インド：インド市場は、医療への投資が増加し、より良い医療サービスを求める患者の要求が高まっていることから、幹細胞治療と非幹細胞治療の両方において新興国市場となっています。最近のインドでは、慢性疾患に対する幹細胞を用いた先進的な治療が開発され、再生医療に特化した新しい研究施設が設立されています。治療費の負担が少ないため、先進医療へのアクセスも向上しています。
• 日本：日本は自己幹細胞治療と非幹細胞治療の両方において、同等の進歩を記録しています。日本では、加齢関連疾患や変性疾患の治療を含む新たな応用に目を向けています。最近の動向としては、神経変性疾患の治療に用いられる細胞治療の成功や、細胞の効率的な採取と処理のための新技術の導入が挙げられます。

よくある質問

Q.1自己幹細胞・非幹細胞治療の市場規模はどのくらいですか？

A1.世界の自己幹細胞・非幹細胞治療市場は、2030年までに推定130億米ドルに達すると予想されています。

Q.2自己幹細胞・非幹細胞治療市場の成長予測は？

A2.世界の自己幹細胞・非幹細胞治療市場は、2024年から2030年にかけてCAGR 10.2%で成長すると予測されています。

Q.3自己幹細胞・非幹細胞治療市場の成長に影響を与える主な促進要因は何ですか？

A3.この市場の主な促進要因は、低侵襲治療に対する需要の高まり、幹細胞・非幹細胞を用いた治療法の急速な技術進歩、再生医療の利用を促進するための政府の支援策の高まりです。

Q4.市場の主要セグメントは：

A4.自己幹細胞・非幹細胞治療市場の将来は、病院市場と外来手術センター市場における機会によって有望視されています。

Q5.市場の主要企業は：

A5.自己幹細胞・非幹細胞治療の主要企業は以下の通りです：

• BrainStorm Cell
• Cytori Therapeutics
• Dendreon Pharmaceuticals
• Novartis
• U.S. Stem Cell

Q6.今後、最大となる市場セグメントは：

A6.Lucintelは、がんと腫瘍は、がんの罹患率と治療法の拡大とともに、自己幹細胞治療の利用が増加しているため、予測期間中に最も高い成長を示すと予測しています。

Q7.市場において、今後5年間に最大になると予想される地域は：

A7.北米は、慢性疾患の有病率の高さ、低侵襲処置に対する大きな需要の存在、および同地域における有利な政府償還政策の利用可能性により、予測期間中に最も高い成長を示すと予想されます。

Q8.レポートのカスタマイズは可能か：

A8.はい、Lucintelは追加費用なしで10%のカスタマイズを提供します。

目次

第1章 エグゼクティブサマリー

第2章 世界の自己幹細胞・非幹細胞治療市場：市場力学

• イントロダクション、背景、分類
• サプライチェーン
• 業界の促進要因と課題

第3章 2018年から2030年までの市場動向と予測分析

• マクロ経済動向（2018～2023年）と予測（2024～2030年）
• 世界の自己幹細胞・非幹細胞治療市場の動向（2018～2023年）と予測（2024～2030年）
• 製品タイプ別自己幹細胞・非幹細胞治療の世界市場
  • 血圧モニタリング装置
  • 肺気圧モニタリング装置
  • 頭蓋内圧モニタリング装置
• 自己幹細胞・非幹細胞治療市場（種類別）
  • 自己幹細胞
  • 自己非幹細胞
• 用途別自己幹細胞・非幹細胞治療の世界市場
  • 神経変性疾患
  • 自己免疫疾患
  • がん・腫瘍
  • 心血管疾患
• 最終用途別世界の自己幹細胞・非幹細胞治療市場
  • 病院
  • 外来手術センター
  • その他

第4章 2018年から2030年までの地域別市場動向と予測分析

• 地域別の世界自己幹細胞・非幹細胞治療市場
• 北米の自己幹細胞・非幹細胞治療市場
• 欧州の自己幹細胞・非幹細胞治療市場
• アジア太平洋の自己幹細胞・非幹細胞治療市場
• その他地域の自己幹細胞・非幹細胞治療市場

第5章 競合分析

• 製品ポートフォリオ分析
• 運用統合
• ポーターのファイブフォース分析

第6章 成長機会と戦略分析

• 成長機会分析
  • 製品タイプ別の世界の自己幹細胞・非幹細胞治療市場の成長機会
  • 世界の自己幹細胞・非幹細胞治療市場における成長機会（種類別）
  • 用途別世界の自己幹細胞・非幹細胞治療市場の成長機会
  • 最終用途別世界の自己幹細胞・非幹細胞治療市場の成長機会
  • 地域別の世界の自己幹細胞・非幹細胞治療市場の成長機会
• 世界の自己幹細胞・非幹細胞治療市場における新たな動向
• 戦略分析
  • 新製品開発
  • 世界の自己幹細胞・非幹細胞治療市場の能力拡大
  • 世界の自己幹細胞・非幹細胞治療市場における合併、買収、合弁事業
  • 認証とライセンシング

第7章 主要企業の企業プロファイル

• BrainStorm Cell
• Cytori Therapeutics
• Dendreon Pharmaceuticals
• Novartis
• U.S. Stem Cell

Autologous Stem Cell and Non-Stem Cell Based Therapy Trends and Forecast

The future of the global autologous stem cell and non-stem cell based therapy market looks promising with opportunities in the hospital and ambulatory surgical center markets. The global autologous stem cell and non-stem cell based therapy market is expected to reach an estimated $13.0 billion by 2030 with a CAGR of 10.2% from 2024 to 2030. The major drivers for this market are growing demand for minimally invasive procedures, rapid technological advancements in stem cell and non-stem cell-based therapies, and rising supportive government initiatives to promote the use of regenerative medicine.

• Lucintel forecasts that cancer & tumor is expected to witness highest growth over the forecast period due to the rising use of autologous therapy along with the expanding incidence of cancer cases and treatments.
• North America is expected to witness highest growth over the forecast period due to the high prevalence of chronic diseases, existence of significant demand for minimally invasive procedures, and availability of favorable government reimbursement policies in the region.

Emerging Trends in the Autologous Stem Cell and Non-Stem Cell Based Therapy Market

Emerging trends in autologous stem cell- and non-stem cell-based therapy markets reveal evolving technology, changes in regulation, and changing clinical application. These are the trends that will reshape the future of regenerative medicine and ensure market growth.

• Greater Emphasis on Personalized Medicine: This increasing personalization of medicines is part of the growing emphasis in the autologous stem cell therapy market. The high level of personalization that has come through the particular genetic profile of the patient has gone a long way in providing increased efficiency with lesser side effects. This trend is, therefore, a push toward more customized therapies for better patient outcomes.
• Cell Processing Technology Advancement: Newer cell-processing technologies are increasing the effectiveness of stem cell treatments. The technological capabilities include automated cell processing and cell expansion methods that yield higher-quality and more numerous therapeutic cells. This will no doubt further enhance the feasibility and scalability of autologous stem cell treatments.
• Clinical Applications Expansion: Clinical applications for both stem cell and non-stem cell-based therapies are set for explosive growth. New treatments are being researched for diseases and injuries affecting the cardiovascular system, the nervous system, and orthopedic ailments. This continues to enhance the platform in which regenerative medicine is being developed while continuing to create more opportunities for market growth.
• Development of Non-Stem Cell Therapies: There has been progress in developing non-pure stem cell-based therapies, such as tissue engineering and gene editing. These represent other modes of regenerative medicine and supplementation of more traditional approaches to treatment that involve the use of stem cells. Such inventions improve the therapeutic options and drive market growth.
• Regulatory Advances and Approvals: Further development of the field through ongoing regulatory efforts will continue to facilitate approval and commercialization for new therapies. Streamlining regulatory processes, along with increased support for innovative treatments, will help further develop and adapt autologous stem cell and non-stem cell-based therapies, allowing better market access and forcing the pace of innovation.

These emerging trends are revolutionizing the autologous stem cell and non-stem cell-based therapy market by advancements in personalized medicine, improved cell processing technologies, expanded clinical uses, development of other alternatives, and smooth regulatory approvals. This, when put together, drives innovation and enhances the effectiveness of regenerative medicine continuously.

Recent Developments in the Autologous Stem Cell and Non-Stem Cell Based Therapy Market

Some of the key developments in autologous stem cell and non-stem cell-based therapies mark the change in technology and clinical practice. This thus denotes that the area of study is dynamic, with an increased impact on health.

• Approval of New Therapies: Adding new autologous stem cell therapies passed by the different bodies like the FDA has increased the scope of therapy and opened up treatment options for patients ailing from chronic diseases and injuries. Other areas include advanced treatments for cardiovascular conditions and autoimmune disorders, active areas reflecting ongoing progress in the field.
• Innovation in Cell Processing: New technologies for cell processing involve automated systems and improved expansion methodologies that make stem cell therapies more effective and powerful. Thus, these advances in the technology are promoting the generation of high-quality therapeutic cells and better access to treatments.
• Growth in Non-Stem Cell-Based Therapies: It is also estimated that the market is significantly growing in the non-stem cell based therapies such as tissue engineering and gene therapy. New frontiers in these fields have now opened up different approaches towards regenerative medicine and supplement traditional approaches based upon the application of stem cells.
• Expansion of Research and Clinical Trials: While research and clinical trials in both autologous stem cell and non-stem cell-based therapies have increased, the same growth brings about new therapies, investigates new applications, and refines the understanding of therapeutic efficacy and safety.
• Advancements in Personalized Treatment: One of the major developments in this market is the creation of treatments personalized to the patient profile. Custom therapies based on genotype and clinical information are improving treatment outcomes and reducing adverse events by moving toward individualized medicine.

These additions are affecting the autologous stem cell and non-stem cell-based therapy market in new therapies, technology of cell processing, expanded research, clinical trials, and personalized treatment approaches. This drives growth that is going to push regenerative medicine to another level of effectiveness.

Strategic Growth Opportunities for Autologous Stem Cell and Non-Stem Cell Based Therapy Market

Growth opportunities in autologous stem cell and non-stem cell-based therapy markets continue to emerge with technological advancement and increasing applications, thus shaping the future in the area of regenerative medicine and further expanding markets.

• Oncology Treatments: Further, oncology represents a huge growth opportunity wherein the use of stem cell therapies is being explored for the treatment and recuperation of cancer. Newer treatment modalities are being offered by advanced cell therapy and tissue engineering techniques for the management and treatment of different types of cancer, along with increasing market potential.
• Cardiovascular Applications: Cardiovascular applications continue to be one of the major growth areas, and the development of stem cell therapies for repair and regeneration of the heart will also occur. Cell-based treatments for cardiovascular disease are producing innovations that are meeting unmet needs and extending treatment options, driving the market growth.
• Neurological Disorders: Treatment of neurological disorders may be considered an emerging growth opportunity. Parkinson's disease and spinal cord injuries are but two examples of medical conditions that are being studied with treatments both involving and not involving the use of stem cells. New avenues for effective treatments thus become available while the circles of market application are expanded.
• Orthopedic Traumas: Other growth areas include orthopaedic injuries and conditions, in which stem cell therapies are considered for the repair of cartilage and regeneration of bone. With recent advances made within regenerative medicine, new solutions have started to be provided to musculoskeletal injuries, improving recovery and contributing to the market growth.
• Monitoring of Diabetes: This, therefore, presents a very important growth opportunity: the management of diabetes with the use of stem cell therapies, including insulin-producing cell regeneration. Diabetes cell-based treatment innovations are opening new frontiers for the management of the disease and improvement of patients' outcomes.

The strategic growth opportunities in autologous stem cell and non-stem cell-based therapy markets are driven by advancements related to oncology, cardiovascular applications, neurological disorders, orthopaedic injuries, and diabetes management. This is a broadening the scope for regenerative medicine and driving innovation across wide therapeutic areas.

Autologous Stem Cell and Non-Stem Cell Based Therapy Market Driver and Challenges

Major drivers and challenges shape the direction of growth and development of the autologous stem cell and non-stem cell-based therapy market. In terms of flux or growth, technological advancement, economic factors, and regulatory considerations have played an influential role in shaping the market.

The factors responsible for driving the autologous stem cell and non-stem cell based therapy market include:

1. Technological Advances: Technological advancements in imaging, cell processing, and therapy techniques are amongst the factors contributing to the growth of the market. Automation of cell processing and advanced genetic editing are amongst the recent innovative concepts improving efficacy and efficiency in both stem cell and non-stem cell-based therapies, hence widening their clinical application scope.

2. Increasing Demand for Regenerative Medicine: The increasing demand for regenerative medicine is one of the major driving factors for the market. Therefore, patients and healthcare providers increasingly need therapies with advanced treatments for chronic and degenerative conditions, thereby fueling the wider adoption of both stem cell and non-stem cell-based therapies. This fosters further market growth and innovation.

3. Clinical Applications Expansion: But this is being driven by the expansion of clinical applications for both stem cell and non-stem cell-based therapies. Further, newer treatments for a range of disease conditions including cancer, cardiovascular diseases, and neurological disorders are expanding the scope of regenerative medicine and increasing market opportunities.

4. Growing Investment in Research and Development: Increased investment in research and development propels innovation into the autologous stem cell-and non-stem cell-based therapy market. This funding emanates from both the public and private sectors and supports the creation and development of new therapies and technologies that drive improvement and competitiveness in the market.

5. Regulatory Support and Approvals: These include support at the regulatory level by way of smooth approval processes: clearer pathways from regulatory bodies for the approval and commercialization of new therapies, better market access, and quickened introduction of new treatments.

Challenges in the autologous stem cell and non-stem cell based therapy market are:

1. Regulatory Hurdles: It is complicated to overcome complex regulatory requirements and make approvals possible by offering new kinds of therapies. The regional variations in regulations would also be very tough when it comes to high-stringency approval processes for the introduction and adoption of new stem cell and non-stem cell-based therapies.

2. High Development Costs: High cost is one of the major challenges in the development or manufacturing process of any advanced therapy. This may be due to costs related to research, development, and production, which could limit accessibility and affordability, especially for more price-sensitive markets. For wider access to the market, cost management becomes an absolute necessity for broader market penetration.

3. Ethical and Safety Issues: Ethical and safety issues with regards to research and therapies involving stem cells are considered some of the most major challenges. Issues of informed consent, risk potential, and long-term results have to be discussed in depth for winning public trust and gaining regulatory approval.

The growth drivers for the autologous stem cell and non-stem cell-based therapy market are technological advancements, increasing demand for regenerative medicine, increasing clinical applications, rising investment in R&D, and regulatory support. Major bottlenecks include regulatory hurdles, high development costs, and ethical issues. With more and more effort being put into addressing these drivers and challenges, better growth and innovation will be achieved in the market.

List of Autologous Stem Cell and Non-Stem Cell Based Therapy Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. Through these strategies autologous stem cell and non-stem cell based therapy companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the autologous stem cell and non-stem cell based therapy companies profiled in this report include-

• BrainStorm Cell
• Cytori Therapeutics
• Dendreon Pharmaceuticals
• Novartis
• U.S. Stem Cell

Autologous Stem Cell and Non-Stem Cell Based Therapy by Segment

The study includes a forecast for the global autologous stem cell and non-stem cell based therapy by product type, type, application, end use, and region.

Autologous Stem Cell and Non-Stem Cell Based Therapy Market by Product Type [Analysis by Value from 2018 to 2030]:

• Blood Pressure Monitoring Devices
• Pulmonary Pressure Monitoring Devices
• Intracranial Pressure Monitoring Devices

Autologous Stem Cell and Non-Stem Cell Based Therapy Market by Type [Analysis by Value from 2018 to 2030]:

• Autologous Stem Cells
• Autologous Non-Stem Cells

Autologous Stem Cell and Non-Stem Cell Based Therapy Market by Application [Analysis by Value from 2018 to 2030]:

• Neurodegenerative Disorders
• Autoimmune Diseases
• Cancer & Tumors
• Cardiovascular Diseases

Autologous Stem Cell and Non-Stem Cell Based Therapy Market by End Use [Analysis by Value from 2018 to 2030]:

• Hospitals
• Ambulatory Surgical Centers
• Others

Autologous Stem Cell and Non-Stem Cell Based Therapy Market by Region [Analysis by Value from 2018 to 2030]:

• North America
• Europe
• Asia Pacific
• The Rest of the World

Country Wise Outlook for the Autologous Stem Cell and Non-Stem Cell Based Therapy Market

The autologous stem cell and non-stem cell-based therapy market has developed a lot in recent times owing to technological innovations and wider clinical applications. These are taking place in the United States, China, Germany, India, and Japan and reflect global developments in regenerative medicine and its incorporation into the mainstream health care system.

• United States: Within the United States, autologous stem cell therapy has seen new therapies currently approved by the FDA, while clinical trials have also been initiated to explore its other uses. The market is observing an upswing in personalized treatments for various indications, including cardiovascular diseases and autoimmune disorders. Improving technologies for cell processing and storage are serving to amplify the efficacy and access associated with these therapies.
• China: Thus, China has advanced in both the stem cell and non-stem cell-based therapies, putting much effort into rapid growth in both clinical research and commercialization. Development in recent times has been, among other things, the development of expanded services for stem cell banking and increased funding in research that relates to regenerative medicine. Chinese institutions explore new treatments for cancer and neurological disorders using advanced stem cell techniques.
• Germany: Nevertheless, Germany is the leader in terms of the integration of autologous stem cell therapies into everyday clinical management, with serious attention to regulatory compliance and, at the same time, effectively providing clinical efficacy. Recent developments in this country include the adoption of new stem cell-based treatments for orthopedic and dermatological conditions. Quality control and patient safety have been emphasized to a very high standard regarding the implementation of therapy in Germany.
• India: The Indian market is a developing market for both stem cell-based therapies and non-stem cell-based therapies, owing to increased investment in the health care and growing demand of patients for better health services. Recently, this country has developed advanced treatments using stem cells for chronic diseases and the establishment of new research facilities with special focus on regenerative medicine. Cost-friendly options for therapies increase access to advanced treatments.
• Japan: Japan has recorded equal progress in both autologous stem cell therapies and non-stem cell-based treatments. The country is looking toward new applications involving the treatment of age-related and degenerative diseases. Recent developments include success with cell therapy used for treating neurodegenerative disorders and new technologies introduced for efficient harvesting and processing of the cells.

Features of the Global Autologous Stem Cell and Non-Stem Cell Based Therapy Market

Market Size Estimates: Autologous stem cell and non-stem cell based therapy market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: Autologous stem cell and non-stem cell based therapy market size by various segments, such as by product type, type, application, end use, and region in terms of value ($B).

Regional Analysis: Autologous stem cell and non-stem cell based therapy market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different product types, types, applications, end uses, and regions for the autologous stem cell and non-stem cell based therapy market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the autologous stem cell and non-stem cell based therapy market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

If you are looking to expand your business in this market or adjacent markets, then contact us. We have done hundreds of strategic consulting projects in market entry, opportunity screening, due diligence, supply chain analysis, M & A, and more.

FAQ

Q.1 What is the autologous stem cell and non-stem cell based therapy market size?

Answer: The global autologous stem cell and non-stem cell based therapy market is expected to reach an estimated $13.0 billion by 2030.

Q.2 What is the growth forecast for autologous stem cell and non-stem cell based therapy market?

Answer: The global autologous stem cell and non-stem cell based therapy market is expected to grow with a CAGR of 10.2% from 2024 to 2030.

Q.3 What are the major drivers influencing the growth of the autologous stem cell and non-stem cell based therapy market?

Answer: The major drivers for this market are growing demand for minimally invasive procedures, rapid technological advancements in stem cell and non-stem cell-based therapies, and rising supportive government initiatives to promote the use of regenerative medicine.

Q4. What are the major segments for autologous stem cell and non-stem cell based therapy market?

Answer: The future of the autologous stem cell and non-stem cell based therapy market looks promising with opportunities in the hospital and ambulatory surgical center markets.

Q5. Who are the key autologous stem cell and non-stem cell based therapy market companies?

Answer: Some of the key autologous stem cell and non-stem cell based therapy companies are as follows:

• BrainStorm Cell
• Cytori Therapeutics
• Dendreon Pharmaceuticals
• Novartis
• U.S. Stem Cell

Q6. Which autologous stem cell and non-stem cell based therapy market segment will be the largest in future?

Answer: Lucintel forecasts that cancer & tumor is expected to witness highest growth over the forecast period due to the rising use of autologous therapy along with the expanding incidence of cancer cases and treatments.

Q7. In autologous stem cell and non-stem cell based therapy market, which region is expected to be the largest in next 5 years?

Answer: North America is expected to witness highest growth over the forecast period due to the high prevalence of chronic diseases, existence of significant demand for minimally invasive procedures, and availability of favorable government reimbursement policies in the region.

Q.8 Do we receive customization in this report?

Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 11 key questions:

• Q.1. What are some of the most promising, high-growth opportunities for the autologous stem cell and non-stem cell based therapy market by product type (blood pressure monitoring devices, pulmonary pressure monitoring devices, and intracranial pressure monitoring devices), type (autologous stem cells and autologous non-stem cells), application (neurodegenerative disorders, autoimmune diseases, cancer & tumors, and cardiovascular diseases), end use (hospitals, ambulatory surgical centers, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
• Q.2. Which segments will grow at a faster pace and why?
• Q.3. Which region will grow at a faster pace and why?
• Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
• Q.5. What are the business risks and competitive threats in this market?
• Q.6. What are the emerging trends in this market and the reasons behind them?
• Q.7. What are some of the changing demands of customers in the market?
• Q.8. What are the new developments in the market? Which companies are leading these developments?
• Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
• Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
• Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?
• Market Report

Table of Contents

1. Executive Summary

2. Global Autologous Stem Cell and Non-Stem Cell Based Therapy Market : Market Dynamics

• 2.1: Introduction, Background, and Classifications
• 2.2: Supply Chain
• 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

• 3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
• 3.2. Global Autologous Stem Cell and Non-Stem Cell Based Therapy Market Trends (2018-2023) and Forecast (2024-2030)
• 3.3: Global Autologous Stem Cell and Non-Stem Cell Based Therapy Market by Product Type
  • 3.3.1: Blood Pressure Monitoring Devices
  • 3.3.2: Pulmonary Pressure Monitoring Devices
  • 3.3.3: Intracranial Pressure Monitoring Devices
• 3.4: Global Autologous Stem Cell and Non-Stem Cell Based Therapy Market by Type
  • 3.4.1: Autologous Stem Cells
  • 3.4.2: Autologous Non-Stem Cells
• 3.5: Global Autologous Stem Cell and Non-Stem Cell Based Therapy Market by Application
  • 3.5.1: Neurodegenerative Disorders
  • 3.5.2: Autoimmune Diseases
  • 3.5.3: Cancer & Tumors
  • 3.5.4: Cardiovascular Diseases
• 3.6: Global Autologous Stem Cell and Non-Stem Cell Based Therapy Market by End Use
  • 3.6.1: Hospitals
  • 3.6.2: Ambulatory Surgical Centers
  • 3.6.3: Others

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

• 4.1: Global Autologous Stem Cell and Non-Stem Cell Based Therapy Market by Region
• 4.2: North American Autologous Stem Cell and Non-Stem Cell Based Therapy Market
  • 4.2.1: North American Autologous Stem Cell and Non-Stem Cell Based Therapy Market by Application: Neurodegenerative Disorders, Autoimmune Diseases, Cancer & Tumors, and Cardiovascular Diseases
  • 4.2.2: North American Autologous Stem Cell and Non-Stem Cell Based Therapy Market by End Use: Hospitals, Ambulatory Surgical Centers, and Others
• 4.3: European Autologous Stem Cell and Non-Stem Cell Based Therapy Market
  • 4.3.1: European Autologous Stem Cell and Non-Stem Cell Based Therapy Market by Application: Neurodegenerative Disorders, Autoimmune Diseases, Cancer & Tumors, and Cardiovascular Diseases
  • 4.3.2: European Autologous Stem Cell and Non-Stem Cell Based Therapy Market by End Use: Hospitals, Ambulatory Surgical Centers, and Others
• 4.4: APAC Autologous Stem Cell and Non-Stem Cell Based Therapy Market
  • 4.4.1: APAC Autologous Stem Cell and Non-Stem Cell Based Therapy Market by Application: Neurodegenerative Disorders, Autoimmune Diseases, Cancer & Tumors, and Cardiovascular Diseases
  • 4.4.2: APAC Autologous Stem Cell and Non-Stem Cell Based Therapy Market by End Use: Hospitals, Ambulatory Surgical Centers, and Others
• 4.5: ROW Autologous Stem Cell and Non-Stem Cell Based Therapy Market
  • 4.5.1: ROW Autologous Stem Cell and Non-Stem Cell Based Therapy Market by Application: Neurodegenerative Disorders, Autoimmune Diseases, Cancer & Tumors, and Cardiovascular Diseases
  • 4.5.2: ROW Autologous Stem Cell and Non-Stem Cell Based Therapy Market by End Use: Hospitals, Ambulatory Surgical Centers, and Others

5. Competitor Analysis

• 5.1: Product Portfolio Analysis
• 5.2: Operational Integration
• 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

• 6.1: Growth Opportunity Analysis
  • 6.1.1: Growth Opportunities for the Global Autologous Stem Cell and Non-Stem Cell Based Therapy Market by Product Type
  • 6.1.2: Growth Opportunities for the Global Autologous Stem Cell and Non-Stem Cell Based Therapy Market by Type
  • 6.1.3: Growth Opportunities for the Global Autologous Stem Cell and Non-Stem Cell Based Therapy Market by Application
  • 6.1.4: Growth Opportunities for the Global Autologous Stem Cell and Non-Stem Cell Based Therapy Market by End Use
  • 6.1.5: Growth Opportunities for the Global Autologous Stem Cell and Non-Stem Cell Based Therapy Market by Region
• 6.2: Emerging Trends in the Global Autologous Stem Cell and Non-Stem Cell Based Therapy Market
• 6.3: Strategic Analysis
  • 6.3.1: New Product Development
  • 6.3.2: Capacity Expansion of the Global Autologous Stem Cell and Non-Stem Cell Based Therapy Market
  • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Autologous Stem Cell and Non-Stem Cell Based Therapy Market
  • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

• 7.1: BrainStorm Cell
• 7.2: Cytori Therapeutics
• 7.3: Dendreon Pharmaceuticals
• 7.4: Novartis
• 7.5: U.S. Stem Cell